Andrea L. Richardson

TBCRC 030: A phase II study of preoperative cisplatin vs. paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker.

C. Perou, E. Winer, L. Trippa, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): Safety and efficacy.

E. Winer, R. Gelman, J. Garber, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer

Jane E. Carpenter, A. Whittemore, W. Chung, 2016, Nature Communications.

Prevalence of BRCA1 mutations in triple negative breast cancer (BC).

S. Schnitt, J. Garber, A. Richardson, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.